Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Microbot Medical, retaining the price target of $12.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily highlighting the recent adoption of Microbot Medical’s LIBERTY endovascular robotic system by Emory University Hospital. This adoption marks a significant commercial milestone for the company, as it is the first hospital to implement the system for patient care. The LIBERTY system, which has just become commercially available in the U.S., is expected to see further adoption by additional hospitals in the near future.
Moreover, the limited market release strategy is designed to gather real-world insights that will guide the system’s full market release in April 2026, ensuring quality and performance. The LIBERTY system is notable for being the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, addressing a substantial market of approximately 2.5 million procedures annually in the U.S. Additionally, the recent patent granted in Japan, along with existing patents in other major markets, strengthens the company’s intellectual property portfolio, which is crucial for protecting and monetizing its technology globally.